Explore the vast range of titles available.

Affective disorders promote poorer outcomes in hemodialysis patients. According to the presence or not of depression/anxiety in these patients, aims were to analyze differences in sociodemographic, clinical and/or psychological factors and to identify predictors. One hundred eighty-six hemodialysis patients were classified based on their depression/anxiety status. Basal characteristics showed differences between groups where mainly male sex (Depression: OR 0.2; Anxiety: OR 0.3) albumin (Depression: OR 0.1; Anxiety: OR 0.2) and calcium levels (Depression: OR 0.5; Anxiety: OR 0.4), impaired quality of life (Depression: OR 1.4; Anxiety: OR 1.2) and psychological inflexibility (Depression: OR 1.3; Anxiety: OR 1.2) were associated (all p < 0.01) to these mental conditions. Multivariate models showed that worse quality of life (OR 1.3; p < 0.001) predicted depression while marital status (with a partner; OR 0.3; p = 0.025) and albumin levels (OR 0.1; p = 0.027) were protective factors. Depression represented a risk factor for anxiety (OR 1.2; p = 0.001), although calcium levels (OR 0.5; p = 0.039) would protect this state. Interestingly, psychological inflexibility predicted both disorders (Depression: OR 1.2, p < 0.001 and Anxiety: OR 1.1; p = 0.002). Results highlight the relevance of well-trained multidisciplinary hemodialysis units to control the influence of these factors on the presence of depression/anxiety, and thus, their impact on the patients’ outcomes.

To assess the effects of intensive follow-up by primary care nurses on cardiovascular disease self-management and compliance behaviours after myocardial infarction. Although cardiovascular disease prevention and cardiac rehabilitation take place in hospital settings, a nurse-led approach is necessary in primary care during the first few months after a myocardial infarction. Therefore, it is important to assess self-management of cardiovascular disease and levels of compliance with the prescribed diet, physical activity, and medication. The study used a multicentre, quasi-experimental, pre-post design without a control group. Patients with acute coronary syndrome from 40 healthcare facilities were included in the study. A total of 212 patients participated in a programme including 11 interventions during the first 12-18 months after myocardial infarction. The following Nursing Outcomes Classification (NOC) outcomes were assessed at baseline and at the end of the intervention: Self-management: Cardiac Disease (1617) and Compliance Behaviour: Prescribed Diet (1622), Compliance Behaviour: Prescribed Activity (1632), and Compliance Behaviour: Prescribed Medication (1623). Marjory Gordon's functional health patterns and a self-care notebook were used in each intervention. Pre-post intervention means were compared using Student's t-tests for related samples. The results of the study are reported in compliance with the TREND Statement. A total of 132 patients completed the intervention. The indicators for each NOC outcome and the variations in scores before and after the intensive follow-up showed a statistically significant improvement (p-value = 0.000). Compliance Behaviour: Prescribed Diet (pre = 3.7; post = 4.1); Compliance Behaviour: Prescribed Activity (pre = 3.9; post = 4.3); Compliance Behaviour: Prescribed Medication (pre = 3.9; post = 4.7). Intensive, immediate follow-up after myocardial infarction improves compliance behaviours and self-management of heart disease. A combined self-care and family care approach should be encouraged to empower post-myocardial infarction patients. To facilitate patients' self-efficacy, the use of health education tools such as a cardiovascular self-care notebook can also be helpful. This study highlights the benefits of intensive, protocolised, comprehensive patient follow-up in primary care during the first few months after an acute myocardial infarction (AMI). Primary care nurses train patients in cardiovascular self-care. Patients were not involved in either the design or the carrying out of the study. However, at the end of the study, they participated in an evaluation process about the utility of the research study and their satisfaction with it. This process was carried out using an ad hoc survey consisting of 10 questions assessing the nursing care and follow-up inputs that were received.

Background/Objectives: Gynecologic carcinosarcomas (GCSs) are rare cancers with poor prognoses. In this study, we aimed to analyze the chemotherapy regimens used to treat GCSs at our institution, as well as the patients’ outcomes. Methods: We conducted a retrospective analysis of 62 GCS patients treated at Hospital Clinico san Carlos (HCSC) from 1995 to 2024. Results: Data from 62 GCSs were analyzed. Fifty-two patients (84%) underwent surgery at diagnosis, followed by radiotherapy in 20 (38.5%) endometrial carcinosarcoma (ECS) patients and perioperative chemotherapy in 45 GCS patients (62.6%). After a median follow-up (mFollow-up) of 20 months (0–242 months), 23 GCS patients relapsed and 13 progressed after the first treatment approach, 3 of them almost immediately after surgery. The median time to disease relapse was 6 months (0–225 months) and the median time to disease progression was 0 months (0–25 months). Sixteen of the relapsing patients and fifteen of the patients who were diagnosed at stage IV received systemic treatment with carboplatin and paclitaxel, the most common forms of chemotherapy (used as first-line treatments in eight of the relapsing patients and in seven patients who were in stage IV at diagnosis). GCS patients received up to five lines. The median progression-free survival (mPFS) was 5 months for the first line, and decreased in the following lines. The median overall survival (mOS) was 24 months (13.5–34.5 months) and 11 months (1–226 months) after GCS relapse/progression. Conclusions: GCS is a rare and aggressive disease with a high recurrence rate after surgery and short progression-free survival (PFS) at advanced stages, even when a combination of oncological therapies are used. (Nevertheless, some patients achieved long disease-free survival). To the best of our knowledge, this is the first publication to provide this valuable data on this rare and aggressive disease, for which phase III and real-world data is scarce.

Introduction/BackgroundGynaecologic carcinosarcomas (GCS) are rare cancers. From 2003 onwards, GCS are no longer considered sarcomas but epithelial carcinomas; thus, shifting their treatment approach. Hospital Clinico San Carlos (HCSC) is EURACAN referral centre for rare gynaecological malignancies since 2022. The objectives of this study are to analyse the behaviour of GCS in our institution, treatment time trends and its impact on survival.MethodologyRetrospective analysis of 57 GCS patients treated in HCSC from 1995 to 2022.ResultsMedian age at diagnosis: 65 years (range 30–90); postmenopausal (98.2%) and ECOG 0 (63%). Median CA125 at diagnosis: 48.4 U/mL (range 5.1- 2130). Primary disease: uterus (80.7%), ovary (17.5%) or vaginal stump (1.8%). Ascites at diagnosis (14%). FIGO staging at diagnosis: I 40.4%, II 14%, III 22.8% and IV 22.8%. 49/57 patients underwent primary surgery (R0 81.6%) including lymphadenectomy in 65.3%. 42/57 patients received chemotherapy: adjuvant 50.9%, neoadjuvant 8.8%, and first line 14%. Two cohorts: up to 2003: 15.8% (9/57) and from 2003 to 2022: 84.2% (48/57). Carboplatin and paclitaxel were used from 2003 in 47.6%. Sequential adjuvant radiotherapy administered in 20/42 (47.6%), only in uterine CS (UCS).After a median follow-up of 20.67 months, median Progression Free Survival (mPFS) and median Overall Survival (mOS) were 16.03 and 25.23 months, respectively. Patients diagnosed from 2003 onwards, have better mOS than those diagnosed before 2003 (40.5 vs 9.7 months, p 0.034), not better mPFS (17.9 vs 7.8 months p 0.415). Ascites (p 0.046), CA125 at diagnosis (p 0.030), >50% of endometrial infiltration in UCS (p 0.041) and incomplete response in the first radiological evaluation (p 0.001) were identified as independent statistically significant poor prognostic factors.ConclusionThe change in treatment approach in GCS since 2003 has improved mOS, probably due to a multidisciplinary approach including surgery, chemotherapy, and radiotherapy.DisclosuresAranzazu Manzano: Receipt of grants/research supports: ASTRA ZENECA (AZ), Receipt of honoraria or consultation fees: AZ, GSK, Participation in a company sponsored speaker’s bureau: AZ, MSD, PHARMAMAR, GSK, ROVI, SANOFI.

This retrospective study evaluated 62 patients with gynecologic carcinosarcomas (GCSs) treated at Hospital Clínico San Carlos (Madrid, Spain) between 1995 and 2024. Most patients underwent surgery followed by platinum-based chemotherapy (mainly carboplatin and paclitaxel) and, in some cases, radiotherapy. Despite this multimodal approach, outcomes remained poor, with a high recurrence rate (58%), a median progression-free survival of 5 months, and a median overall survival of 24 months. This study presents the first real-world evidence on the disease control rate, mPFS, and mOS of second and subsequent treatment lines in GCS patients, including information about the treatments administered in each line. These findings confirm the aggressive nature and limited treatment options for GCS, highlighting the urgent need for further research and novel therapies.

Currently, brachytherapy is the most commonly used therapeutic approach for uveal melanomas. Surgical resection by means of endoresection or exoresection is an alternative approach. The present report recounts our experience over 15 years in the treatment of uveal melanoma using a combined approach of resection surgery with brachytherapy. This is a single-center observational retrospective cohort study in which we describe clinical outcomes, complications and survival in 35 cases of melanoma of the iris or the ciliary body after a combination of surgery and brachytherapy or brachytherapy alone. Local treatment of the tumor was successful in all cases with surgery and brachytherapy. The most frequent complications were scleromalacia, bullous keratopathy, retinal toxicity, cataracts, hypotonia, and photophobia. There were three cases of recurrence, all of which were found in the group of patients who had received brachytherapy alone, and in one case we had to perform a secondary enucleation due to tumor growth after brachytherapy. At present, only one patient has died during follow-up due to liver metastases six years after the start of treatment. In carefully selected patients, this approach can be effective and safe, as long as a close follow-up is carried out after surgery.

FRIDA is a diffraction-limited imager and integral-field spectrometer that is being built for the adaptive-optics focus of the Gran Telescopio Canarias. In imaging mode FRIDA will provide scales of 0.010, 0.020 and 0.040 arcsec/pixel and in IFS mode spectral resolutions of 1500, 4000 and 30,000. FRIDA is starting systems integration and is scheduled to complete fully integrated system tests at the laboratory by the end of 2017 and to be delivered to GTC shortly thereafter. In this contribution we present a summary of its design, fabrication, current status and potential scientific applications.